Study of Biomarkers GDF-15, MR proADM, and Presepsin in Adults Aged 18-65 With Acute Coronary Syndrome, Pneumonia, and COPD, Considering Influenza Vaccination

What this Trial Is About

This research investigates the connection between specific biomarkers and health outcomes in patients with Acute Coronary Syndrome ACS who also have Pneumonia and Chronic Obstructive Pulmonary Disease COPD. The study aims to understand how the levels of Growth Differentiation Factor 15 GDF-15, Mid Regional proAdrenomedullin MR proADM, and Presepsin relate to inflammation and clinical status, particularly in those who have received Influenza vaccinations. Researchers want to see if these biomarkers can provide more detailed insights into the patients conditions and the impact of prior immunizations. Participants are randomly assigned to receive either an influenza tetravalent vaccine called Vaxigrip or a placebo injection. Alongside this, they will continue to receive standard pneumonia treatments and may undergo procedures like percutaneous coronary intervention for ACS. The study monitors biomarker levels at hospital admission and for up to 30 days after vaccination to compare changes between groups. This phase 3 trial includes a triple masking design to ensure unbiased results. During the study, participants will have clinical assessments for ACS, pneumonia, and COPD, and provide their influenza vaccination history. Blood samples will be collected to measure the biomarker levels at baseline and 4 weeks post-vaccination. Researchers track changes in these markers to evaluate inflammation and response to vaccination. The total participation involves follow-up visits and biomarker evaluations to analyze how vaccination status affects these inflammatory proteins over time.

Analysis of Growth Differentiation Factor 15 (GDF-15), Mid Regional proAdrenomedullin (MR proADM), and Persepsin Levels in Patient in Acute Coronary Syndrome Patients With Pneumonia, With or Without Influenza Vaccination